Therapeutics

Oculis plans to commence its PIONEER program, consisting of 3 trials, by the end of the year.

Phentolamine ophthalmic solution 0.75% is for the treatment of significant, chronic night driving impairment in keratorefractive patients with reduced mesopic vision.

Understand the anatomical risks, technique-specific benefits, and patient selection criteria

Advances address a need for the growing populace with age-related near vision loss.

RAMQ is a public organization introduced in 1970, following the adoption of the universal health care system in Canada.

Marguerite B. McDonald, MD, FACS, shares a front-row view of ophthalmology’s “revolution with a capital R."

Tirzepatide and semaglutide show favorable ocular safety compared to traditional weight loss formulations

The annual Best Hospitals report from US News & World Report compares more than 4500 hospitals across 15 specialties and 22 procedures and conditions.

At the CCOI-Stanford Summit, Goldberg calls for collaborative trial models that could redefine efficiency and standardization in ophthalmology research.

Pinguecula is a benign, common degeneration of the conjunctiva that appears as a grey-white-yellow mass on the bulbar conjunctiva.

In honor of Ophthalmology Times’ 50th anniversary, anterior segment surgeons attending ASCRS 2025 weigh in on the innovations that defined modern ophthalmology.

Intracameral tPA can treat fibrinous clots in severe anterior uveitis.

Timely diagnosis and personalized treatment are key to improving visual outcomes.

Amneal Pharmaceuticals received FDA approval for its prednisolone acetate ophthalmic suspension, a steroid eye inflammation treatment referencing Allergan’s Pred Forte, with a US launch planned for Q3 2025.

Harrow expects BYQLOVI to be commercially available in the fourth quarter of 2025.

On the heels of the drug's FDA approval, clinicians weigh in on acoltremon’s (Tryptyr) novel mechanism of action and its potential to address unmet needs in dry eye care

Weighing the benefits and trade-offs of preserved versus preservative-free glaucoma treatments is key to optimizing long-term patient care.

Discover how real-world evidence shapes cataract surgery practices, highlighting user satisfaction with enhanced monofocal IOLs at the 2025 ASCRS Annual Meeting.

Discover how dropless cataract surgery enhances patient comfort and outcomes, reducing the need for eye drops and improving recovery efficiency.

Chinese researchers reveal that low-level red light therapy may control myopia in children but raises concerns about retinal damage and cone density reduction.

ENTOD Pharmaceuticals launches Myatro XL, a 0.05% atropine eye drop, to effectively slow myopia progression in children, available by prescription in 2025.

Personalizing treatment options and setting realistic expectations are crucial.